Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Jun 18;9:e55957. doi: 10.7554/eLife.55957

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2020, Bozal-Basterra et al

This article is distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use and redistribution provided that the original author and source are credited.

PMC Copyright notice

Figure 7. — (A, B) Graphical representation of the fold-change in the expression of Gli1 (n = 5) (A) and Ptch1 (n = 7) (B) obtained by qRT-PCR from wild-type Shh-LIGHT2 cells (WT; blue dots) or Shh-LIGHT2 cells lacking Luzp1 (Luzp1^-/-; orange dots), treated (+) or not (-) with purmorphamine for 24 hr. (C) Western blot analysis of lysates from WT and Luzp1^-/- cells. Samples were probed against GLI3 using an antibody that detects both GLI3-activator form (GLI3-A) and GLI3-repressor form (GLI3-R); GAPDH was used as loading control. Numbers under the lanes are the Mean of 3 independent experiments, resulting of dividing the activator by the repressor intensities, taking WT non-induced value as 1. Molecular weight markers are shown to the right. (D, E) Graphical representation of fold-change in luciferase activation when WT (n > 7; blue dots), Luzp1^-/- (n > 7; orange dots) or +LUZP1 (n = 4; green dots) cells are treated for 6 and 24 hr or not (-) with purmorphamine. (E) Each treated condition was normalized against its respective non treated condition, taking the non-induced value as 1 (dashed line). All graphs represent the Mean and SEM. P-values were calculated using two-tailed unpaired Student´s t-test or One-way ANOVA and Bonferroni post-hoc test.

Figure 7—figure supplement 1. — (A, B) Graphical representation of the fold-change in the expression of Gli1 (n = 5) (A) and Ptch1 (n = 7) (B) obtained by qRT-PCR from wild-type Shh-LIGHT2 cells (WT; blue dots) or Shh-LIGHT2 cells lacking Luzp1 (Luzp1^-/-; orange dots), treated (+) or not (-) with purmorphamine for 24 hr. (C) Western blot analysis of lysates from WT and Luzp1^-/- cells. Samples were probed against GLI3 using an antibody that detects both GLI3-activator form (GLI3-A) and GLI3-repressor form (GLI3-R); GAPDH was used as loading control. Numbers under the lanes are the Mean of 3 independent experiments, resulting of dividing the activator by the repressor intensities, taking WT non-induced value as 1. Molecular weight markers are shown to the right. (D, E) Graphical representation of fold-change in luciferase activation when WT (n > 7; blue dots), Luzp1^-/- (n > 7; orange dots) or +LUZP1 (n = 4; green dots) cells are treated for 6 and 24 hr or not (-) with purmorphamine. (E) Each treated condition was normalized against its respective non treated condition, taking the non-induced value as 1 (dashed line). All graphs represent the Mean and SEM. P-values were calculated using two-tailed unpaired Student´s t-test or One-way ANOVA and Bonferroni post-hoc test.